ELCIN: Elacestrant in women and men with CDK4/6 inhibitor (CDK4/6i)-naïve estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer (mBC)—An open-label multicenter phase 2 study.

Authors: Virginia G. Kaklamani, Giorgi Dzagnidze, Nicoleta Zenovia Antone, Anu Thummala, Mikheil Janjalia, Patricia Xavier Santi, Carlos H. Barrios, Mehmet Ali Nahit Sendur, Xiaoling Zhang, Angela Gambioli, Manuel Domínguez Lizarbe, Kathy Puyana Theall, Tomer Wasserman, William John Gradishar

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps1127

Source: Full article

---

Abstract

TPS1127